Rheumatoid arthritis interstitial lung disease: Mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug

Archives of Internal Medicine

Volumn 168, Issue 15, 2008, Pages 1718-1719

  Saketkoo, Lesley Ann ^a   Espinoza, Luis R ^b  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXYGEN; PREDNISONE;

ARTIFICIAL VENTILATION; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; HUMAN; INTERSTITIAL LUNG DISEASE; LETTER; LUNG ALVEOLITIS; OXYGEN THERAPY; POLYMYOSITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYNOVITIS; SYSTEMIC SCLEROSIS; WHEELCHAIR;

ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MYCOPHENOLIC ACID; POLYMYOSITIS; QUALITY OF LIFE; SCLERODERMA, SYSTEMIC; SYNOVITIS; TREATMENT OUTCOME;

EID: 49449101589     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.15.1718     Document Type: Letter

References (14)

1. Gochuico BR, Avila NA, Chow CK, Novero LJ. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168(2):159-166.
2. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax. 2001;56(8):622-627.
3. Metafratzi ZM, Georgiadis AN, Ioannidou CV, et al. Pulmonary involvement in patients with early rheumatoid arthritis. Scand J Rheumatol. 2007;36(5):338-344.
4. Saketkoo LA, Espinoza LR. promising effects of mycophenolate mofetil on autoimmune related pulmonary fibrosis [abstract 27]. Arthritis Rheum. 2007;56(9)(suppl):S62.
5. Mamelok R. From mechanisms to long-term benefits. Transplantation. 2005;79(3)(suppl):S43-S44.
6. Morath C, Schewenger V, Beimler J, et al. Anti-fibrotic actions of mycophenolic acid. Clin Transplant. 2006;20(suppl 17):25-29.
7. Roos N, Poulalhon N, Farge D, Madelaine I, Mauviel A, Verrecchia F. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther. 2007;321(2):583-589.
8. Yang YF, Tan DM, Xie YT, Zhao W, Hou ZH, Zhong YD. Mycophenolate mofetil prevents lethal acute liver failure in mice induced by bacille Calmette-Guérin and lipopolysaccharide. J Gastroenterol Hepatol. 2008;23(4):611-618.
9. Shimizu H, Takahashi M, Takeda S, et al. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation. 2004;77(11):1661-1667.
10. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease Chest. 2006;130(1):30-36.
11. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2008;133(2):455-460.
12. Liossis SNC, Bounas A, Andonopoulos AP. Mycophenolate mofetil as firstline treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford). 2006;45(8):1005-1008.
13. Zamora AC, Wolters PJ, Collard HR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008;102(1):150-155.
14. Tashkin DP, Elashoff R, Clements PJ, et al; Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176(10):1026-1034.